NCT05851066

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

A Phase 1 Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of VSA003 in Chinese Adult Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Visirna Therapeutics HK Limited · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst

Conditions

• Dyslipidemias
• Familial Hypercholesterolemia
• Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	VSA003	sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
DRUG	0.9% NaCl	placebo

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-05-07
• Completion: 2024-05-07
• First posted: 2023-05-09
• Last updated: 2025-09-12

Locations

1 site across 1 country: China